AtheroGenics to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008
30 Avril 2008 - 4:57PM
Marketwired
ATLANTA, GA , a pharmaceutical company focused on the treatment
of chronic inflammatory diseases, today announced its participation
in the 2008 Morgan Stanley Global Healthcare Unplugged Conference
on Friday, May 2, 2008 at 11:20 a.m. EDT.
The conference will feature its "Unplugged" presentation format
with Morgan Stanley analysts hosting company management in an
informal and interactive discussion with the investment
community.
A live webcast of the Company's presentation may be accessed
from 'Investor Relations' on the Company's website at
www.atherogenics.com. The replay of the webcast will also be
available on the Company's website for two weeks following the
presentation. To ensure a timely connection, it is recommended that
users register at least 15 minutes prior to the scheduled
webcast.
About AtheroGenics
AtheroGenics is focused on the discovery, development and
commercialization of novel drugs for the treatment of chronic
inflammatory diseases, including diabetes and coronary heart
disease (atherosclerosis). The Company's lead antioxidant and
anti-inflammatory drug candidate, AGI-1067, is being studied in a
Phase III clinical trial known as ANDES (AGI-1067 as a Novel
Anti-Diabetic Agent Evaluation Study), for the treatment of
diabetes. In addition, the Company has other clinical and
preclinical anti-inflammatory compounds, including AGI-1096, an
oral agent for the prevention of organ transplant rejection. For
more information about AtheroGenics, please visit
http://www.atherogenics.com.
CONTACTS: AtheroGenics, Inc. Donna Glasky Corporate
Communications 678-336-2517 Email Contact Media Inquiries Jayme
Maniatis / Dana Conti Schwartz Communications, Inc. 781-684-0770
Email Contact Investor Inquiries Lilian Stern Stern Investor
Relations, Inc. 212-362-1200 Email Contact
Atherogenics (NASDAQ:AGIX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Atherogenics (NASDAQ:AGIX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Atherogenics (MM) (NASDAQ): 0 recent articles
Plus d'articles sur AtheroGenics, Inc.